## Abstract A novel matrix metalloproteinase inhibitor, ABT‐518, [__S__‐(__R__^\*^, __R__^\*^)]‐__N__‐[1‐(2, 2‐dimethyl‐1,3‐dioxol‐4‐yl)‐2‐[[4‐[4‐(trifluoromethoxy)‐phenoxy]phenyl]sulfonyl]ethyl]‐__N__‐hydroxyformamide, was labeled with tritium in two phenyl rings in a seven‐step synthesis. The ove
The Development of a Large-Scale Synthesis of Matrix Metalloproteinase Inhibitor, ABT-518
✍ Scribed by Chang, Sou-Jen; Fernando, Dilinie; Fickes, Michael; Gupta, Ashok K.; Hill, David R.; McDermott, Todd; Parekh, Shyamal; Tian, Zhenping; Wittenberger, Steven J.
- Book ID
- 127386322
- Publisher
- American Chemical Society
- Year
- 2002
- Tongue
- English
- Weight
- 86 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1083-6160
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The MMPI [^14^C]ABT‐770 **(1)**, __N‐__[__(1S)__‐1‐[(4,4‐Dimethyl‐2,5‐dioxo‐1‐imi‐dazolidinyl)methyl]]‐2‐[[4′‐(trifluoromethoxy)[1,1′‐biphenyl]‐4‐yl]oxy]ethyl]‐__N__‐hydroxyformamide was synthesized in 8 steps using 4‐bromophenol‐UL‐^14^C **(10)** as a starting material. The Carbon‐14 l
A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of (R)-tert-butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of it